PharmiWeb1d
Breast Cancer Therapeutics Market (2024-2035)
Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...
Targeted Oncology2d
Adjuvant T-DM1 Outperforms Trastuzumab in HER2-Positive Early Breast Cancer
Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
Science Daily7d
Trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
JD Supra8d
FDA Accepts BLA for Shanghai Henlius Biotech’s HLX11, a Pertuzumab Biosimilar
Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...
Targeted Oncology11d
T-DM1 Shows Tolerability in HER2+ Biliary Tract Adenocarcinoma
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...
Cancer Therapy Advisor26d
Adjuvant T-DM1 Provides Long-Term Benefits Over Trastuzumab in HER2+ Breast Cancer
The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...
MedPage Today29d
Adding Palbociclib to Standard Care Improved PFS in Triple-Positive Breast Cancer
after a first course of chemotherapy and dual blockade and HER2 blockade with pertuzumab [Perjeta]/trastuzumab [Herceptin], usually treat with the maintenance treatment with pertuzumab/trastuzumab ...